☰

Minu K. Srivastava, Ph.D. - Publications

Affiliations: 
2009 Biological Sciences University of Maryland, Baltimore County, Baltimore, MD, United States 
Area:
Cell Biology, Immunology
Tree Info Similar researchers PubMed Report error

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Nabet BY, Hamidi H, Lee MC, Banchereau R, Morris S, Adler L, Gayevskiy V, Elhossiny AM, Srivastava MK, Patil NS, Smith KA, Jesudason R, Chan C, Chang PS, Fernandez M, et al. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell. PMID 38366589 DOI: 10.1016/j.ccell.2024.01.010  0.414
2021 Filbert EL, Björck PK, Srivastava MK, Bahjat FR, Yang X. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application. Cancer Immunology, Immunotherapy : Cii. PMID 33392713 DOI: 10.1007/s00262-020-02814-2  0.37
2019 Kluger H, Weiss SA, Olszanski AJ, Schuchter L, Linette GP, Garland L, Iannotti NO, Johnson M, Avsar E, Srivastava MK, Trifan OC, Edelman MJ. Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC) Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct089  0.346
2018 Park AI, Srivastava MK, Yun R, Pokorny J, Yu J, Axelrod F, Gurney A. Abstract 70: Effect of aging on the antitumor activity of GITRL-Fc Cancer Research. 78: 70-70. DOI: 10.1158/1538-7445.Am2018-70  0.46
2017 Tan YC, Mirzapoiazova T, Won BM, Zhu L, Srivastava MK, Vokes EE, Husain AN, Batra SK, Sharma S, Salgia R. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Scientific Reports. 7: 9192. PMID 28835699 DOI: 10.1038/S41598-017-09078-4  0.307
2017 Srivastava MK, Yun R, Mayes E, Yu J, Jie H, Axelrod F, Xie M, Monteon J, Lam A, Ji M, Liu Y, Lewicki J, Hoey T, Gurney A, Park AI. Abstract 2612: Anti-Tigit induces T cell mediated anti-tumor immune response and combines with immune checkpoint inhibitors to enhance strong and long term anti-tumor immunity Cancer Research. 77: 2612-2612. DOI: 10.1158/1538-7445.Am2017-2612  0.583
2017 Park AI, Srivastava M, Mayes E, Jie H, Yun R, Murriel C, Xie M, Lam A, Ji M, Axelrod F, Monteon J, Lewicki J, Hoey T, Gurney A. Abstract 2003: Antibody against TIGIT (T cell immunoreceptor with Ig and ITIM domains) induces anti-tumor immune response and generates long-term immune memory Cancer Research. 77: 2003-2003. DOI: 10.1158/1538-7445.Am2017-2003  0.592
2016 Vences-Catalán F, Rajapaksa R, Srivastava MK, Marabelle A, Kuo CC, Levy R, Levy S. Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis. Oncoimmunology. 5: e1120399. PMID 27467918 DOI: 10.1080/2162402X.2015.1120399  0.571
2016 Axelrod F, Jie H, Mayes E, Monteon J, Srivastava M, Yun R, Park IA, Gurney A. Abstract A058: GITRL-Fc, an immunotherapeutic agent that stimulates T-cell-mediated antitumor immune response Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A058  0.552
2016 Jie H, Srivastava MK, Mayes E, Yun R, Axelrod F, Monteon J, Gurney A, AIP. Abstract 3215: GITRL-Fc can significantly reduce tumor growth by stimulating innate and adaptive immunity Cancer Research. 76: 3215-3215. DOI: 10.1158/1538-7445.Am2016-3215  0.516
2016 Srivastava MK, Yun R, Mayes E, Jie H, Axelrod F, Monteon J, Xie M, Lewicki J, Hoey T, Gurney A, Park AI. Abstract 2214: GITR ligand fusion protein (GITRL-Fc) induces T cell mediated anti-tumor immune response and can combine with anti-PDL1 to enhance anti-tumor immunity and long-term immune memory Cancer Research. 76: 2214-2214. DOI: 10.1158/1538-7445.Am2016-2214  0.548
2016 Vences-Catalán F, Rajapaksa R, Srivastava MK, Marabelle A, Kuo CC, Levy R, Levy S. Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis Oncoimmunology. DOI: 10.1080/2162402X.2015.1120399  0.334
2015 Vences-Catalan F, Rajapaksa R, Srivastava MK, Marabelle A, Kuo CC, Levy R, Levy S. Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells. Cancer Research. PMID 26329536 DOI: 10.1158/0008-5472.Can-15-1021  0.582
2015 Zhu LX, Davoodi M, Srivastava MK, Kachroo P, Lee JM, St John M, Harris-White M, Huang M, Strieter RM, Dubinett S, Sharma S. GITR agonist enhances vaccination responses in lung cancer. Oncoimmunology. 4: e992237. PMID 26137407 DOI: 10.4161/2162402X.2014.992237  0.511
2015 Srivastava M, Murriel C, Yun R, Mayes E, Jie H, Axelrod F, Xie M, Bentley T, Cancilla B, Tam R, O'Young G, Kapoun A, Lewicki J, Hoey T, Gurney A, et al. Co-targeting of delta-like ligand 4 (DLL4) and vascular endothelial growth factor a (VEGF) with programmed death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P373  0.466
2015 Srivastava M, Murriel CL, Roda J, Jie H, Axelrod F, Xie M, Yun R, Mayes E, Bentley T, Cancilla B, Tam R, Tang T, Kapoun A, Lewicki J, Hoey T, et al. Abstract 255: Dual targeting of Delta-like ligand 4 (DLL4) and programmed death 1(PD1) inhibits tumor growth and generates enhanced long-term immunological memory Cancer Research. 75: 255-255. DOI: 10.1158/1538-7445.Am2015-255  0.483
2014 Vences Catalan F, Rajapaksa R, Srivastava MK, Marabelle A, Levy S. The Tetraspanin CD81 Facilitates Tumor Metastasis By Modulating Immune Suppression Blood. 124: 4136-4136. DOI: 10.1182/Blood.V124.21.4136.4136  0.601
2012 Srivastava MK, Zhu L, Harris-White M, Huang M, St John M, Lee JM, Salgia R, Cameron RB, Strieter R, Dubinett S, Sharma S. Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. Immunotargets and Therapy. 2012: 7-12. PMID 24791250 DOI: 10.2147/ITT.S32617  0.446
2012 Srivastava MK, Dubinett S, Sharma S. Targeting MDSCs enhance therapeutic vaccination responses against lung cancer. Oncoimmunology. 1: 1650-1651. PMID 23264925 DOI: 10.4161/Onci.21970  0.471
2012 Srivastava MK, Zhu L, Harris-White M, Kar UK, Kar U, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett S, Sharma S. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. Plos One. 7: e40677. PMID 22815789 DOI: 10.1371/Journal.Pone.0040677  0.431
2012 Srivastava MK, Andersson Å, Zhu L, Harris-White M, Lee JM, Dubinett S, Sharma S. Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy. 4: 291-304. PMID 22401635 DOI: 10.2217/Imt.11.178  0.452
2011 Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S. Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. Journal of Immunology (Baltimore, Md. : 1950). 186: 6822-9. PMID 21555531 DOI: 10.4049/Jimmunol.1003682  0.692
2010 Srivastava MK, Bosch JJ, Wilson AL, Edelman MJ, Ostrand-Rosenberg S. MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells. International Journal of Cancer. 127: 2612-21. PMID 20473949 DOI: 10.1002/Ijc.25462  0.694
2010 Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Research. 70: 68-77. PMID 20028852 DOI: 10.1158/0008-5472.Can-09-2587  0.653
2010 Bosch JJ, Iheagwara UK, Reid S, Srivastava MK, Wolf J, Lotem M, Ksander BR, Ostrand-Rosenberg S. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells. Cancer Immunology, Immunotherapy : Cii. 59: 103-12. PMID 19557412 DOI: 10.1007/S00262-009-0729-0  0.691
2010 Beury DW, Fitzgerald P, Srivastava MK, Ostrand-Rosenberg S. Abstract 1922: Do stress response genes play a role in maintaining MDSC survival and suppression Cancer Research. 70: 1922-1922. DOI: 10.1158/1538-7445.Am10-1922  0.639
2008 Srivastava MK, Bosch JJ, Thompson JA, Ksander BR, Edelman MJ, Ostrand-Rosenberg S. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunology, Immunotherapy : Cii. 57: 1493-504. PMID 18322683 DOI: 10.1007/S00262-008-0490-9  0.75
2008 Thompson JA, Srivastava MK, Bosch JJ, Clements VK, Ksander BR, Ostrand-Rosenberg S. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes. Cancer Immunology, Immunotherapy : Cii. 57: 389-98. PMID 17724589 DOI: 10.1007/S00262-007-0381-5  0.721
2007 Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Research. 67: 4499-506. PMID 17483366 DOI: 10.1158/0008-5472.Can-06-3770  0.721
2007 Bunt SK, Hanson EM, Sinha P, Srivastava MK, Clements VK, Ostrand-Rosenberg S. Tumor-Associated Myeloid-Derived Suppressor Cells Cancer Immunotherapy. 309-331. DOI: 10.1016/B978-012372551-6/50081-X  0.69
Show low-probability matches.